A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Moderate ThrombocytopeniaMyelofibrosis
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, Bulgaria
🇧🇬University Hospital Sv.Ivan Rilski - Sofia, Sofia, Bulgaria
🇫🇷CHU Tours, Hôpital Bretonneau Service d'Hématologie thérapie cellulaire, Tours Cedex 01, Indre-et-Loire, France
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
- Conditions
- Endometrial Cancer
- Interventions
- Drug: Matching Placebo for selinexor
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 220
- Registration Number
- NCT05611931
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸Jupiter Medical Center, Jupiter, Florida, United States
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT04854434
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
🇺🇸BRCR Global, Plantation, Florida, United States
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Conditions
- Locally Advanced Unresectable or Metastatic Melanoma
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 15
- Registration Number
- NCT04768881
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸TOI Clinical Research, Pasadena, California, United States
🇺🇸BRCR Global, Plantation, Florida, United States
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04562389
- Locations
- 🇺🇸
UAB Division of Hematology/Oncology, Birmingham, Alabama, United States
🇺🇸UCLA - Satellite Site, Encino, California, United States
🇺🇸City of Hope, Duarte, California, United States
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- Other: Physician's Choice Treatment
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 112
- Registration Number
- NCT04562870
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Pasadena, California, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States
🇺🇸Illinois Cancer Specialist, Niles, Illinois, United States
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Relapsed/refractory Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Placebo matching for Selinexor (combination therapy)Drug: Placebo matching for Selinexor (continuous therapy)
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 501
- Registration Number
- NCT04442022
- Locations
- 🇺🇸
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The Oncology Institute (TOI) Clinical Research, Cerritos, California, United States
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation: Standard Fractionated Radiation therapy (RT)Device: TTField
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04421378
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States
🇺🇸University of California, San Francisco, California, United States
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- Conditions
- Multiple Myeloma, Refractory
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 127
- Registration Number
- NCT04414475
- Locations
- 🇬🇷
University General Hospital of Patras, Patra, Achaia, Greece
🇬🇷General Hospital of Athens "ALEXANDRA", Attiki, Athens, Greece
🇬🇷General Hospital of Athens "Evaggelismos", Athens, Attiki, Greece